Author(s)

Baofeng Liu¹, Yuanmei Dai¹, Xiaohui Shen¹, Xiangyang Tian^2*

¹Department of Gastroenterology, Heping Hospital of Changzhi Medical College, Changzhi, China.
²Department of Oncology, Heping Hospital of Changzhi Medical College, Changzhi, China.

Antibody drug conjugates (ADCs) are a new class of drugs that combine chemosynthetic drugs with antibody drugs through a linker. Antibody drug conjugates combine the targeting characteristics of traditional antibody drugs with the cytotoxic characteristics of small molecule drugs, while reducing the side effects of both drugs, making them a kind of “biological missile” and representing a relatively new and evolving class of anti-cancer drugs. Antibody-coupled drugs are currently used in many solid tumors, and this article reviews the clinical application of antibody-coupled drugs in HER2-positive gastric cancer.

Antibody-Coupled Drugs, HER2-Positive Gastric Cancer, Review

Liu, B. , Dai, Y. , Shen, X. and Tian, X. (2023) Antibody-Coupled Drugs in HER2-Positive Gastric Cancer. Journal of Biosciences and Medicines, 11, 9-17. doi: 10.4236/jbm.2023.117002.